DS
RIGL icon

David Shaw’s Rigel Pharmaceuticals RIGL Stock Holding History

David Shaw’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2M Buy
542,539
+96,861
+22% +$2.99M 0.01% 1254
2026
Q1 		$12.1M Buy
445,678
+21,362
+5% +$718K 0.01% 1491
2025
Q4 		$18.2M Buy
424,316
+117,827
+38% +$4.44M 0.01% 1308
2025
Q3 		$8.68M Buy
+306,489
New +$9.17M ﹤0.01% 1800
2023
Q1 		– Sell
-335,290
Closed -$5.03M – 4793
2022
Q4 		$5.03M Sell
335,290
-129,356
-28% -$1.19M 0.01% 2094
2022
Q3 		$5.48M Buy
464,646
+117,192
+34% +$1.59M 0.01% 1986
2022
Q2 		$3.93M Buy
347,454
+294,081
+551% +$5.91M ﹤0.01% 2422
2022
Q1 		$1.6M Buy
53,373
+45,144
+549% +$1.22M ﹤0.01% 3521
2021
Q4 		$218K Sell
8,229
-4,666
-36% -$141K ﹤0.01% 4834
2021
Q3 		$468K Buy
+12,895
New +$508K ﹤0.01% 4128
2021
Q1 		– Sell
-4,667
Closed -$163K – 4430
2020
Q4 		$163K Sell
4,667
-9,299
-67% -$269K ﹤0.01% 3764
2020
Q3 		$335K Sell
13,966
-86,975
-86% -$2.14M ﹤0.01% 3402
2020
Q2 		$1.85M Buy
100,941
+60,525
+150% +$1.09M ﹤0.01% 2473
2020
Q1 		$630K Sell
40,416
-3,981
-9% -$84.7K ﹤0.01% 3078
2019
Q4 		$950K Sell
44,397
-9,965
-18% -$205K ﹤0.01% 3030
2019
Q3 		$1.02M Buy
54,362
+29,306
+117% +$605K ﹤0.01% 2818
2019
Q2 		$654K Buy
25,056
+15,953
+175% +$360K ﹤0.01% 2934
2019
Q1 		$234K Sell
9,103
-2,228
-20% -$50.9K ﹤0.01% 3336
2018
Q4 		$261K Sell
11,331
-12,048
-52% -$340K ﹤0.01% 3429
2018
Q3 		$750K Sell
23,379
-41,017
-64% -$1.23M ﹤0.01% 2867
2018
Q2 		$1.82M Sell
64,396
-17,808
-22% -$634K ﹤0.01% 2292
2018
Q1 		$2.91M Sell
82,204
-73,639
-47% -$2.95M ﹤0.01% 1771
2017
Q4 		$6.05M Buy
155,843
+4,723
+3% +$180K 0.01% 1363
2017
Q3 		$3.84M Buy
151,120
+15,591
+12% +$379K 0.01% 1576
2017
Q2 		$3.7M Sell
135,529
-26,336
-16% -$721K 0.01% 1559
2017
Q1 		$5.36M Buy
161,865
+16,349
+11% +$417K 0.01% 1247
2016
Q4 		$3.46M Sell
145,516
-46,663
-24% -$1.34M 0.01% 1572
2016
Q3 		$7.05M Sell
192,179
-49,836
-21% -$1.43M 0.01% 1088
2016
Q2 		$5.4M Sell
242,015
-14,471
-6% -$360K 0.01% 1238
2016
Q1 		$5.33M Buy
256,486
+12,486
+5% +$308K 0.01% 1226
2015
Q4 		$7.39M Buy
244,000
+14,650
+6% +$444K 0.01% 1153
2015
Q3 		$5.67M Buy
229,350
+4,877
+2% +$146K 0.01% 1313
2015
Q2 		$7.21M Buy
224,473
+16,875
+8% +$645K 0.01% 1220
2015
Q1 		$7.41M Buy
207,598
+51,866
+33% +$1.42M 0.01% 1137
2014
Q4 		$3.54M Buy
155,732
+4,598
+3% +$93K ﹤0.01% 1825
2014
Q3 		$2.93M Sell
151,134
-14,315
-9% -$404K ﹤0.01% 1939
2014
Q2 		$6.01M Buy
165,449
+3,175
+2% +$108K 0.01% 1481
2014
Q1 		$6.3M Buy
162,274
+13,064
+9% +$466K 0.01% 1399
2013
Q4 		$4.25M Buy
149,210
+39,664
+36% +$1.16M 0.01% 1824
2013
Q3 		$3.92M Buy
109,546
+26,702
+32% +$974K 0.01% 1825
2013
Q2 		$2.77M Buy
+82,844
New +$3.75M 0.01% 1824

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

David Shaw's RIGL Position: Q2 2026 in Review

David Shaw increased its Rigel Pharmaceuticals (RIGL) stake by 22% in Q2 2026, buying an estimated $2.99M and bringing the position to 542,539 shares worth $21.2M. The position accounts for 0.01% of the portfolio, ranked #1254.

David Shaw first reported a position in RIGL in Q2 2013 and has held it in 41 quarters since. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • David Shaw held 542,539 shares of Rigel Pharmaceuticals worth $21.2M as of Q2 2026.
  • David Shaw bought 96,861 Rigel Pharmaceuticals shares in Q2 2026, an estimated $2.99M.
  • Rigel Pharmaceuticals made up 0.01% of David Shaw's portfolio in Q2 2026, its #1254 holding.
  • David Shaw first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.